42.13
+2.12(+5.30%)
Currency In USD
| Previous Close | 40.01 |
| Open | 40.7 |
| Day High | 42.35 |
| Day Low | 40.31 |
| 52-Week High | 57.72 |
| 52-Week Low | 20.85 |
| Volume | 553,735 |
| Average Volume | 704,579 |
| Market Cap | 1.56B |
| PE | -150.46 |
| EPS | -0.28 |
| Moving Average 50 Days | 40.77 |
| Moving Average 200 Days | 32.23 |
| Change | 2.12 |
If you invested $1000 in Harrow Health, Inc. (HROW) 10 years ago, it would be worth $7,021.67 as of October 20, 2025 at a share price of $42.13. Whereas If you bought $1000 worth of Harrow Health, Inc. (HROW) shares 5 years ago, it would be worth $7,646.1 as of October 20, 2025 at a share price of $42.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ImprimisRx Announces Leadership Changes
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solu
Harrow to Acquire Melt Pharmaceuticals
GlobeNewswire Inc.
Sep 26, 2025 11:00 AM GMT
NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc.,
Harrow Launches Harrow Access for All (HAFA)
GlobeNewswire Inc.
Sep 25, 2025 8:05 PM GMT
HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal NASHVILLE, Tenn., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading prov